PTC Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on PTC Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date PTC Therapeutics Inc Strategy Report
- Understand PTC Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
PTC Therapeutics Inc (PTC Therapeutics) discovers, develops, and markets medicines for the treatment of rare disorders. Its marketed products include Evrysdi (risdiplam) for spinal muscular atrophy, Translarna (ataluren) and Emflaza (deflazacort) for the treatment of Duchenne muscular dystrophy. The company's pipeline candidates target the treatment of Huntington’s disease; children with inherited mitochondrial disease; leiomyosarcoma; acute myelogenous leukemia; and aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics works in collaboration with various biotechnology and pharmaceutical companies for advancing its pipeline candidates. It operates through its subsidiaries in the US and Europe. PTC Therapeutics is headquartered in South Plainfield, New Jersey, the US.
Headquarters
United States of America
Address
100 Corporate Ct, South Plainfield, New Jersey, 07080-2400
Website
www.ptcbio.com
Telephone
1 908 2227000
No of Employees
1,402
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PTCT (NASD)
Revenue (2022)
$698.8M
29.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-6.7%
(2022 vs 2021)
Market Cap*
$2.0B
Net Profit Margin (2022)
XYZ
17.8%
(2022 vs 2021)
* As of and is in US$
PTC Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Translarna (Ataluren): Duchenne Muscular Dystrophy | Evrysdi |
| Emflaza (Deflazacort): Duchenne Muscular Dystrophy | Translarna |
| Waylivra (Volanesorsen): Familial Chylomicronemia Syndrome | Emflaza |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In October, the company entered into an agreement with Royalty Pharma to monetize up to US$1.5 billion of the royalty stream for the spinal muscular atrophy drug Evrysdi (risdiplam). |
| 2022 | Financing Agreements | In October, the company signed a strategic financing partnership worth up to US$1 billion with funds managed by Blackstone to back the development of innovative product pipeline. |
| 2022 | Contracts/Agreements | In July, the company announced a partnership with Saphetor to advance awareness of clinical programs in rare diseases. |
Competitor Comparison
| Key Parameters | PTC Therapeutics Inc | Astellas Pharma Inc | Biogen Inc | Daiichi Sankyo Co Ltd | Nippon Shinyaku Co Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | Japan | United States of America | Japan | Japan |
| City | South Plainfield | Chuo-Ku | Cambridge | Chuo-Ku | Kyoto-Shi |
| State/Province | New Jersey | Tokyo | Massachusetts | Tokyo | Kyoto |
| No. of Employees | 1,402 | 14,484 | 8,725 | 17,435 | 2,186 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Schmertzler | Chairman | Executive Board | 2004 | 71 |
| Matthew B. Klein, M.D. | Director; Chief Executive Officer | Executive Board | 2023 | 51 |
| Emily Hill | Chief Financial Officer | Senior Management | 2019 | 43 |
| Christine Utter | Head - People Services; Senior Vice President; Chief Accounting Officer | Senior Management | 2019 | 45 |
| Mark E. Boulding | Executive Vice President; Chief Legal Officer | Senior Management | 2012 | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward